Search results
Regeneron Pharmaceuticals Inc TradeGate Stock Price Today | NASDAQ REGN Live Ticker - Investing.com
Investing.com· 30 minutes agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
2 Biotech Stocks to Buy in May
Motley Fool via Yahoo Finance· 24 minutes agoLet's consider two such stocks in the biotech industry: Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals& ...
Regeneron EVP LaRosa sells shares worth over $1.85 million By Investing.com
Investing.com· 3 days agoRegeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) executive vice president and general...
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?
Simply Wall St. via Yahoo Finance· 3 days ago(NASDAQ:REGN) as an investment opportunity by taking the forecast future cash flows of the company...
Dynamic Technology Lab Private Ltd Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 2 days agoDynamic Technology Lab Private Ltd purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron ...
NBC 10 - FOX 14 Monroe· 3 days agoPomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information...
Benzinga via AOL· 20 hours agoU.S. drug wholesaler Cencora Inc (NYSE:COR), formerly AmerisourceBergen, is notifying affected...
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
Motley Fool via Yahoo Finance· 2 days agoNvidia (NASDAQ: NVDA), Netflix (NASDAQ: NFLX), and Regeneron Pharmaceuticals (NASDAQ: REGN) have ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results from an ongoing Phase 1/2 trial evaluating its first-in-class ...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at...
Benzinga· 5 days agoDupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly